945. Deputy Joe Cooney asked the Minister for Health the reasons the drug acarizax is not included in either the medical card scheme or the drugs payment scheme; if she will consider the inclusion of the drug; and if she will make a statement on the matter. [17057/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
949. Deputy John Lahart asked the Minister for Health the approval process for bempedoic acid (nilemdo) under the drugs payment scheme; the reason for delays in processing individual applications for this medication; if she will ensure that applicants who have exceeded the monthly DPS threshold while awaiting approval will be reimbursed in full; and if she will make a statement on the matter. [17075/26]
951. Deputy Cian O'Callaghan asked the Minister for Health if she will commit to prioritising the reimbursement process for omaveloxolone to ensure that it is made available to the approximately 200 people in Ireland living with Friedreich’s ataxia; if she recognises the clinical necessity of this treatment for a community that currently has no other therapeutic options; and if she will make a statement on the matter…
959. Deputy John McGuinness asked the Minister for Health if versatis pain patches will be made available to a person (details supplied); and if she will make a statement on the matter. [17156/26]
966. Deputy John Brady asked the Minister for Health for an update on the use of the drug xolair for allergies; the status of applications to the HSE to fund the use of this drug in limited circumstances for allergies; and if she will make a statement on the matter. [17186/26]
510. Deputy Ken O'Flynn asked the Minister for Health the incremental cost-effectiveness ratio, cost per QALY gained, time horizon applied, and discount rate used in the full health technology assessments conducted by the National Centre for Pharmacoeconomics in respect of tirzepatide for type 2 diabetes mellitus and weight management; and whether lifetime modelling assumptions were applied in either assessment. [158…
511. Deputy Ken O'Flynn asked the Minister for Health whether the health technology assessments conducted in respect of tirzepatide included modelling of downstream healthcare cost offsets arising from reductions in incidence of type 2 diabetes; cardiovascular events; hospital admissions; and obesity-related complications; and to provide the percentage reductions assumed in each case within the base-case analysis. [1…
512. Deputy Ken O'Flynn asked the Minister for Health the projected gross and net annual budget impact, and five-year cumulative budget impact, of reimbursement of tirzepatide for weight management under the current eligibility criteria outlined by the HSE; and the estimated eligible patient population used in the budget impact model. [15813/26]
513. Deputy Ken O'Flynn asked the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes. [15814/26]
514. Deputy Ken O'Flynn asked the Minister for Health the reasons for the duration between commissioning and completion of the full health technology assessment of tirzepatide for type 2 diabetes; and whether her Department has conducted any review of timelines in the medicines assessment process since 2023. [15815/26]
548. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 315 of 11 February 2025, and noting that the National Centre for Pharmacoeconomics completed a full health technology assessment of tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus on 9 February 2026, and for weight management on 3 December 2025, whether she has been notified of t…
549. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has prepared or received any gross and net budget impact analysis in respect of the proposed reimbursement of tirzepatide and semaglutide for diabetes and weight management indications; the estimated annual gross cost to the Exchequer in each of the first five years of potential reimbursement; any estimated downstream cost offsets…
550. Deputy Ken O'Flynn asked the Minister for Health the estimated number of adults nationally who meet the clinical eligibility thresholds outlined in the completed HTAs for tirzepatide for diabetes and weight management indications; the estimated number of adolescents who would meet the subpopulation criteria proposed for semaglutide reimbursement; whether her Department has been advised of projected uptake rates;…
551. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any comparative assessment of the timeframe from marketing authorisation to reimbursement decision for GLP-1 receptor agonists in Ireland relative to other EU Member States; whether she considers the current pharmacoeconomic assessment and negotiation timeline proportionate to the scale of the public health burden posed by obe…
552. Deputy Ken O'Flynn asked the Minister for Health whether formal commercial negotiations between the HSE Corporate Pharmaceutical Unit and the relevant marketing authorisation holders in respect of tirzepatide and semaglutide are currently active; whether any price proposal has been received following completion of the HTA processes; whether any budget ceiling or access cap has been set as a matter of Departmenta…
617. Deputy John McGuinness asked the Minister for Health if the drug sky clarys (omaveloxolone) used for the treatment of Friedreichs ataxia will be made available under licence in Ireland; if she will outline the process to licence the drug; the timeline involved; and if she will make a statement on the matter. [16033/26]
1109. Deputy Michael Cahill asked the Minister for Health to urgently examine and allow for a continuous glucose monitors on the long term illness scheme for a person (details supplied); and if she will make a statement on the matter. [15157/26]
560. Deputy Ken O'Flynn asked the Minister for Health whether the Primary Care Reimbursement Service holds reimbursement claims data for salbutamol nebules dispensed under the general medical services scheme from 1 January 2025 to date; and if so, to provide the total number of claims and the monthly breakdown [13447/26]
561. Deputy Ken O'Flynn asked the Minister for Health whether the Primary Care Reimbursement Service holds reimbursement claims data for alternative nebulised bronchodilator products dispensed under the general medical services scheme from 1 January 2025 to date; and if so, to provide the total number of claims and the monthly breakdown, including identification of the relevant product categories [13448/26]
562. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE conducted any national analysis of prescribing substitution patterns arising from reported shortages of salbutamol nebules since 1 January 2025; and if so, to provide details of the methodology used and any conclusions reached [13449/26]
563. Deputy Ken O'Flynn asked the Minister for Health the national monitoring framework which is in place within her Department or the HSE to assess the patient impact of essential medicine shortages under the general medical services scheme; and whether this framework includes tracking of clinical substitution, cost impact, or regional variation [13450/26]
564. Deputy Ken O'Flynn asked the Minister for Health whether any additional expenditure has arisen under the general medical services scheme as a result of prescribing alternative products due to salbutamol nebule shortages since 1 January 2025; and if so, to provide the estimated amount and the basis of calculation [13451/26]
588. Deputy Ken O'Flynn asked the Minister for Health the number of claims submitted under the General Medical Services Scheme, Drugs Payment Scheme and Long-Term Illness Scheme for salbutamol nebules or equivalent short-acting bronchodilator nebule products in (a) 2024 and (b) 2025; the number and value of such claims paid; the number and value rejected or unpaid; and whether she will provide the corresponding figur…
589. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the Health Service Executive maintains centralised data on the number of patients whose access to reimbursable salbutamol nebules or equivalent substitute products was impacted during registered shortage periods in 2024 and 2025; if so, the number recorded; and if not, whether she intends to introduce a monitoring mechanism to quantify pa…
590. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment, clinical safety review, or value-for-money analysis was conducted in relation to the ongoing shortages of salbutamol nebules during 2024 and 2025; whether contingency procurement arrangements were activated; and what governance structures are in place to ensure uninterrupted reimbursement access for essential respiratory medicin…